
Dec 23 (Reuters) - A patient who was being treated with Pfizer's hemophilia drug, Hympavzi, as part of a long-term study died after experiencing serious side effects, the company said.
The individual died on December 14 after suffering a stroke followed by a brain hemorrhage, according to the European Haemophilia Consortium, a patient support group.
The patient was enrolled in a study that was testing Hympavzi in patients with hemophilia A or B with or without inhibitors.
"Pfizer, together with the trial investigator and the independent external Data Monitoring Committee, are actively gathering information to better understand the complex, multi-factorial circumstances surrounding this occurrence," the company said in a statement.
The therapy, a once-a-week injection, gained U.S. approval last year to prevent or reduce bleeding episodes in hemophilia A or B patients aged 12 years and older by targeting blood-clotting proteins.
Pfizer does not anticipate any impact to safety for patients treated with the drug based on its current knowledge and the overall clinical data collected to date, the company said.
People with hemophilia have a defect in a gene that regulates the production of proteins called clotting factors, causing spontaneous and severe bleeding following injuries or surgery.
Earlier this year, Pfizer said it would halt global development and commercialization of its hemophilia gene therapy, Beqvez, citing soft demand from patients and their doctors.
Beqvez, a one-time therapy, was approved in the U.S. for the treatment of adults with moderate to severe hemophilia B.
(Reporting by Sneha S K in Bengaluru; Editing by Anil D'Silva)
LATEST POSTS
- 1
Interpreter Starts Sobbing as 11-Year-Old Testifies About Last Time He Saw His Mom Before She Was Killed in Missile Strike - 2
The Land Rover Freelander Is Back—But It’s No Longer a Land Rover - 3
7 Methods for further developing Rest Quality - 4
NASA's Artemis 2 moon launch may be visible from Florida and southern Georgia today. Here's when to look - 5
NASA's Artemis astronauts enter final preparations for Moon mission
Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
Pick the Ideal Family Feline Variety for Your Home
Partake in the Outside: Senior-Accommodating Exercises for 2024
Flourishing in a Cutthroat Work Market: Vocation Methodologies
5 Christmas movies to stream for less with this Paramount+ Black Friday deal
SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video)
Report: Russian military pressuring students to work as drone pilots
New law puts familiar drinks, creams and gummies in legal limbo
SpaceX's 1st 'Version 3' Super Heavy Starship booster buckles under pressure during initial tests













